NeuroSense Reports Positive Preliminary Results from Alzheimer’s Biomarker Study
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense’s drug for treatment of Alzheimer’s disease. NeuroSense's biomarker study identified several biomarkers associated with AD, which indicate CogniC's mechanism of action...